進行性パーキンソン病患者におけるレシゴンの有効性と安全性に関する長期観察研究 (ELEGANCE)
ELEGANCE - 定期治療中の進行性パーキンソン病患者におけるレボドパ-エンタカポン-カルビドパ腸内ゲル (Lecigon®) の長期有効性と安全性に関する非介入研究
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.
In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Study design:
Non-interventional study, primary data collection.
No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.
The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.
The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.
Primary Objectives:
- Long-term effectiveness of Lecigon®
- Long-term safety of Lecigon®
Secondary Objectives:
- Patient non-motor symptoms and quality of life
- Healthcare resource utilisation by patients
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
-
Dublin、アイルランド、D07 R2WY
- The Dublin Neurological Institute, Mater Hospital
-
Dublin、アイルランド、D04 T6F4
- St. Vincent's University Hospital
-
-
-
-
-
Groningen、オランダ、97139713
- University Medical Center Groningen
-
-
-
-
-
Graz、オーストリア、8036
- Universitätsklinik für Neurologie, Medizinische Universität Graz
-
Hermagor、オーストリア、9620
- Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
-
Innsbruck、オーストリア、6020
- Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
-
Linz、オーストリア、4020
- Kepler Universitätsklinikum
-
-
-
-
-
Osijek、クロアチア、31000
- UHC Osijek, J. Klinici za neurologiju
-
Rijeka、クロアチア
- University Hospital Centre Rijeka (KBC Rijeka)
-
Zagreb、クロアチア、10000
- University Hospital Centre (KBC Zagreb)
-
Zagreb、クロアチア、10000
- Klinička bolnica Dubrava
-
-
-
-
-
Gothenburg、スウェーデン、413 45
- Sahlgrenska University Hospital
-
Lund、スウェーデン
- Skånes universitetssjukhus Lund
-
Uppsala、スウェーデン、751 85
- Uppsala university hospital
-
-
-
-
-
Barcelona、スペイン、08025
- Hospital de la Santa Creu i Sant Pau
-
Madrid、スペイン、28040
- Hospital Clínico San Carlos
-
Madrid、スペイン、28034
- Hospital Universitario Ramón y Cajal
-
Madrid、スペイン
- Hospital de la Princesa
-
Seville、スペイン、41013
- Hospital Virgen del Rocio
-
-
-
-
-
Ljubljana、スロベニア、1000
- Department of Neurology, University Medical Centre
-
Maribor、スロベニア、2000
- Univerzitetni klinični center Maribor
-
-
-
-
-
Brno、チェコ
- Masaryk university
-
Olomouc、チェコ
- Fakultní nemocnice Olomouc
-
-
-
-
-
Copenhagen、デンマーク、2400
- Bispebjerg Hospital
-
-
-
-
-
Bad Segeberg、ドイツ、23795
- Segeberger Kliniken GmbH Neurologisches Zentrum
-
Beelitz-Heilstätten、ドイツ、14547
- Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
-
Berlin、ドイツ、10117
- Charité - Universitätsmedizin Berlin
-
Cologne、ドイツ
- Uniklinik Köln
-
Coppenbrügge、ドイツ、31863
- Krankenhaus Lindenbrunn
-
Essen、ドイツ、45147
- Klinik für Neurologie - Universitätsklinikum Essen
-
Freiburg im Breisgau、ドイツ、79106
- Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
-
Göttingen、ドイツ、37075
- Zentrum für Seltene Erkrankungen Göttingen
-
Marburg、ドイツ、35043
- Universitätsklinikum Giessen und Marburg
-
Oldenburg、ドイツ、26122
- Evangelisches Krankenhaus Oldenburg
-
Osnabrück、ドイツ、49076
- Klinikum Osnabrück GmbH Klinik für Neurologie
-
Tübingen、ドイツ、72076
- Universitätsklinikum Tübingen
-
Ulm、ドイツ、89081
- RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
-
Wolfach、ドイツ、77709
- Parkinson-Klinik Ortenau
-
-
-
-
-
Budapest、ハンガリー
- Semmelweis Egyetem Neurológiai Klinika Budapest
-
Pécs、ハンガリー、7623
- Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
-
Szeged、ハンガリー、6725
- SZTE Szent-Györgyi Albert Klinikai Közpon
-
-
-
-
-
Sofia、ブルガリア、1113
- Sveti Naum
-
-
-
-
-
Bruges、ベルギー、8000
- AZ Sint-Jan
-
Edegem、ベルギー、2650
- Antwerp University Hospital
-
Ghent、ベルギー
- Ghent University Hospital
-
Liège、ベルギー
- University Hospital Liege
-
Tournai、ベルギー、7500
- Centre Hospitalier de Wallonie picarde (Chwapi)
-
-
-
-
-
Brasov、ルーマニア、500326
- Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
-
Bucharest、ルーマニア、050098
- Bucharest University Emergency Hospital
-
Bucharest、ルーマニア
- Fundeni Clinical Institute
-
Bucharest、ルーマニア、011461
- Spitalul Universitar de Urgență Elias
-
Bucharest、ルーマニア、020125
- Colentina Hospital Bucharest
-
Cluj-Napoca、ルーマニア、400347
- County Emergency Hospital Cluj-Napoca
-
Constanța、ルーマニア、900591
- County Clinical Emergency Hospital of Constanta
-
Timișoara、ルーマニア、300723
- Timiş County Emergency Clinical Hospital- Neurology 1
-
Timișoara、ルーマニア、300723
- Timiş County Emergency Clinical Hospital
-
Târgu Mureş、ルーマニア、540136
- Emergency County Hospital Targu Mures
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Treating physician's normal patient pool
説明
Inclusion Criteria:
- Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
- Patients or legal representative must have signed informed consent to participate in the study
- Patients are not taking part in another clinical (interventional) study at the same time
Exclusion Criteria:
- Patients with contraindications as defined in the current version of the SmPC for Lecigon®
- Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
- Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications) |
24 months
|
|
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living) |
24 months
|
|
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses |
24 months
|
|
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected |
24 months
|
|
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I) |
24 months
|
|
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C) |
24 months
|
|
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
時間枠:24 months
|
To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item. |
24 months
|
|
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
時間枠:24 months
|
To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected |
24 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS) |
24 months
|
|
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2) |
24 months
|
|
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living) |
24 months
|
|
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39) |
24 months
|
|
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit |
24 months
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
時間枠:24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation |
24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- NIS-MA-2020-02
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。